Showing results (551-560 of 599) with videos related to
Sort By:
Pageof 60
Current Pharmaceutical Design|June 21, 2022
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing TherapiesClodoveo Ferri, Vincenzo Raimondo, Laura Gragnani, et al.Arthritis Care & Research|December 30, 2025
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRYEnrico De Lorenzis, Gerlando Natalello, Rossella De Angelis, et al.Current Pharmaceutical Design|September 3, 2021
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing TreatmentsClodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, et al.RMD Open|May 13, 2026
Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for RheumatologyVeronica Batani, Ilaria Cavazzana, Martina Orlandi, et al.RMD Open|December 10, 2024
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysisAlexis F Guédon, Fabrice Carrat, Luc Mouthon, et al.Journal of Autoimmunity|April 21, 2026
Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR databaseFlorian Käs, Muriel Elhai, Mike O Becker, et al.Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.Annals of the Rheumatic Diseases|January 18, 2026
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)Liubov Petelytska, Lorenzo Tofani, Arthiha Velauthapillai, et al.Annals of the Rheumatic Diseases|August 17, 2012
TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patientsEugénie Koumakis, Julien Wipff, Philippe Dieudé, et al.Pageof 60